Gilead Sciences Unusual Options Activity For September 20
Today, Benzinga's options scanner spotted 9 options trades for Gilead Sciences. This is not a typical pattern. The sentiment ...
Hold Rating on Gilead Sciences Amid Lenacapavir’s Promise and Market Uncertainties
Leerink Partners analyst Daina Graybosch has maintained their neutral stance on GILD stock, giving a Hold rating on September 12. “Daina ...
Yahoo Finance10d
Gilead Sciences, Inc. (GILD)
Twice-yearly lenacapavir also demonstrated sup Gilead stock popped Thursday after the biotech giant said its twice-yearly shot prevented 99.9% of HIV infections in a study. Gilead Sciences rose ...
FiercePharma2d
Gilead taps Korea's Yuhan to supply HIV drug ingredients in $81M deal
In the latest supply deal on the active pharmaceutical ingredients (API) front, Gilead Sciences has tapped South Korea’s ...
Buy Rating on Gilead Sciences: Underestimated Market Potential of Lenacapavir in HIV Treatment and Prevention
J.P. Morgan analyst Chris Schott has maintained their bullish stance on GILD stock, giving a Buy rating on September 13. Chris Schott has ...
Yahoo Finance5d
Gilead Sciences (GILD) Stock Sinks As Market Gains: Here's Why
Gilead Sciences (GILD ... shows that these estimate changes are directly correlated with near-term stock prices. To capitalize on this, we've crafted the Zacks Rank, a unique model that ...
FiercePharma3d
Gilead's Kite exits China cell therapy joint venture with Fosun Pharma
Gilead Sciences’ Kite Pharma will sell its stake in China’s Fosun Kite Biotechnology nearly eight years after forming the ...